Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  Sandin, Linda C ^a   Tötterman, Thomas H ^a   Mangsbo, Sara M ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Antibody; Bladder cancer; CD40; Local immunotherapy

Indexed keywords

CP 870893;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; DRUG ADMINISTRATION ROUTE; EXPERIMENTAL BLADDER CANCER; EXPERIMENTAL NEOPLASM; HUMAN; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; PERITUMORAL DRUG ADMINISTRATION;

EID: 84899094050     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27400     Document Type: Article

References (10)

1. Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, Solsona E, Di Stasi SM, Witjes JA. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009; 56:247-56; PMID:19409692; http://dx.doi.org/10.1016/j.eururo.2009.04.038.
2. Askeland EJ, Newton MR, O'Donnell MA, Luo Y. Bladder Cancer Immunotherapy: BCG and Beyond. Adv Urol 2012; 2012:181987; PMID:22778725; http://dx.doi.org/10.1155/2012/181987.
3. Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Tötterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 2010; 33:225-35; PMID:20445343; http://dx.doi.org/10.1097/CJI.0b013e3181c01fcb.
4. Mangsbo SM, Ninalga C, Essand M, Loskog A, Tötterman TH. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. J Immunother 2008; 31:34-42; PMID:18157010; http://dx.doi.org/10.1097/CJI.0b013e3181587d29.
5. Lindqvist C, Sandin LC, Fransson M, Loskog A. Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition. J Immunother 2009; 32:785-92; PMID:19752755; http://dx.doi.org/10.1097/CJI.0b013e3181acea69.
6. Loskog AS, Fransson ME, Totterman TT. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model. Clin Cancer Res 2005; 11:8816-21; PMID:16361570; http://dx.doi.org/10.1158/1078-0432.CCR-05-1817.
7. Malmström PU, Loskog AS, Lindqvist CA, Mangsbo SM, Fransson M, Wanders A, Gårdmark T, Tötterman TH. AdCD40L immunogene therapy for bladder carcinoma-the first phase I/IIa trial. Clin Cancer Res 2010; 16:3279-87; PMID:20448220; http://dx.doi.org/10.1158/1078-0432.CCR-10-0385.
8. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007; 25:876-83; PMID:17327609; http://dx.doi.org/10.1200/JCO.2006.08.3311.
9. Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res 2011; 17:2270-80; PMID:21389097; http://dx.doi.org/10.1158/1078-0432.CCR-10-2888.
10. Sandin LC, et al. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunology Research 2013; In press; http://dx.doi.org/10.1158/2326-6066.CIR-13-0067.